Section

General

No CPD Points

Course Summary

Polly Dulley & Philip Morgan (15:23)

Tamoxifen had resurfaced in 2013 in the media because of NICE guidelines which approved the drug for prescription not only to patients with a diagnosis, but also to those at high risk of developing breast cancer. Polly Dulley and Philip Morgan discuss the clinical impact that the NICE guidelines may have on optometrists.

First published in DOCET OQ87 (2013).

    Open all

    Instructions: Clicking on the section name will show / hide the section.

    View only 'Topic 1'

    To provide listeners with:

    • An overview of Tamoxifen, how it works and why it is so widely used
    • An outline of the NICE guideline relating to Tamoxifen
    • An outline of the ocular side-effects, how to examine for them, and how common they are
    • An indication of what an optometrist should bear in mind when dealing with a patient taking Tamoxifen
    • An indication of the impact the NICE guidelines will have on the numbers of patients optometrists see
      View only 'Topic 2'
      View only 'Topic 3'

      References:

      • Dulley P, Senior J (2003) Tamoxifen: a review of drug development for use in breast cancer and ocular adverse reactions. Optometry in Practice 4, 117–127
      • Dulley, P (1999) Ocular adverse reactions to tamoxifen - a review. Ophthal. Physiol. Opt. 19, S2–S9
        View only 'Topic 4'

        Please give your feedback on this course. Please click on the link below to launch the evaluation form.